BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ariceta G, Fakhouri F, Sartz L, Miller B, Nikolaou V, Cohen D, Siedlecki AM, Ardissino G. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clinical Kidney Journal 2021;14:2075-84. [DOI: 10.1093/ckj/sfab005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Baskin E, Fidan K, Gulhan B, Gulleroglu K, Canpolat N, Yilmaz A, Parmakiz G, Ozcakar BZ, Ozaltin F, Soylemezoglu O. Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study. J Nephrol. [DOI: 10.1007/s40620-021-01212-w] [Reference Citation Analysis]